LONG MINI-FUTURE - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 11:17:05 24/05/2024 pm IST | ||
| 0.45 EUR | -13.46% |
|
| Current month | -4.26% | ||
| 1 month | -30.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 0.45 | -13.46% |
| 23/24/23 | 0.52 | -21.21% |
| 22/24/22 | 0.66 | +8.20% |
| 21/24/21 | 0.61 | -11.59% |
| 20/24/20 | 0.69 | +2.99% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 11:17 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VV3YFJ |
| ISIN | DE000VV3YFJ1 |
| Date issued | 17/06/2022 |
| Strike | 60.66 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.14 € |
|---|---|
| Lowest since issue | 0.31 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.68
USD
Average target price
82.77
USD
Spread / Average Target
+26.03%
- Stock Market
- Certificates
- Certificat
